Eric Schmidt, SandboxAQ chairman (Susan Walsh/AP Images)
June 22, 2023 02:18 PM EDTUpdated June 23, 07:18 AM
Deals

As­traZeneca, Sanofi turn to Al­pha­bet spin­out's AI and quan­tum tech­nolo­gies for drug dis­cov­ery

Zachary Brennan

Senior Editor

As part of its bio­phar­ma R&D ac­cel­er­a­tion ef­forts, an Al­pha­bet spin­out an­nounced to­day that it’s work­ing with As­traZeneca, Sanofi and oth­ers on drug dis­cov­ery and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times